Navigation Links
Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Adrian Schwarzer, MD, Ph.D. to its Scientific Advisory Committee

MILLBROOK, N.Y., Dec. 23, 2013 /PRNewswire/ -- Dr. Schwarzer is affiliated with Hannover Medical School in Hannover, Germany at the Institute of Experimental Hematology and resident in the Department of Hematology, Oncology and Stem Cell Transplantation. Dr. Schwarzer has an MD in Immunology and Ph.D. in Molecular Medicine/Biochemistry. He is currently engaged in investigating the role of cap dependent translation in acute lymphoblastic leukemias with a special focus on T-ALL.

We at Egenix are delighted to have Dr. Schwarzer aboard and feel confident that he will make significant contributions to the advancement of science and medicine.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit


SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. KaloBios Appoints Donald R. Joseph as Chief Legal Officer
2. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
3. Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™
4. Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
5. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
6. The Leukemia & Lymphoma Societys "A Tribute to Jackie" Photo Collection Part of Auction Commemorating the 50th Anniversary of President Kennedys Assassination
7. TrialNetworks Co-founder and Chairman Vivek Murthy, MD, MBA, Nominated by President Barack Obama as Surgeon General of the United States of America
8. ISPE Names Dr. Thomas Zimmer as Vice President of European Operations
9. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
10. Sigma-Aldrich Corporation Delcares Quarterly Dividend Of $0.215 Per Share And Announces Election Of New Vice President And Treasurer
11. Gentris Corporation Partners with BioFortis, Announces New Vice President of Information Technology
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):